0001437749-23-000587.txt : 20230105 0001437749-23-000587.hdr.sgml : 20230105 20230105210846 ACCESSION NUMBER: 0001437749-23-000587 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230103 FILED AS OF DATE: 20230105 DATE AS OF CHANGE: 20230105 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mathew Aby J. CENTRAL INDEX KEY: 0001556355 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36362 FILM NUMBER: 23513512 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: #310 CITY: BOTHELL STATE: WA ZIP: 98021 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOLIFE SOLUTIONS INC CENTRAL INDEX KEY: 0000834365 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 943076866 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 4254011400 MAIL ADDRESS: STREET 1: 3303 MONTE VILLA PARKWAY STREET 2: SUITE 310 CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: BIOLIFE SOLUTION INC DATE OF NAME CHANGE: 20030113 FORMER COMPANY: FORMER CONFORMED NAME: CRYOMEDICAL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 rdgdoc.xml FORM 4 X0306 4 2023-01-03 0000834365 BIOLIFE SOLUTIONS INC BLFS 0001556355 Mathew Aby J. C/O BIOLIFE SOLUTIONS, INC. 3303 MONTE VILLA PARKWAY, SUITE 310 BOTHELL WA 98021 1 EVP & Chief Scientific Officer Common Stock 2023-01-03 4 M 0 9500 2.06 A 262326 D Common Stock 2023-01-03 4 S 0 9500 17.72 D 252826 D Common Stock 2023-01-03 4 M 0 500 2.06 A 253326 D Common Stock 2023-01-03 4 S 0 500 18.81 D 252826 D Common Stock 2023-01-04 4 M 0 500 2.06 A 253326 D Common Stock 2023-01-04 4 S 0 500 17.71 D 252826 D Common Stock 2023-01-04 4 M 0 9500 2.06 A 262326 D Common Stock 2023-01-04 4 S 0 9500 18.49 D 252826 D Employee Stock Option 2.06 2023-01-03 4 M 0 10000 0 D 2025-05-04 Common Stock 10000 180000 D Employee Stock Option 2.06 2023-01-04 4 M 0 10000 0 D 2025-05-04 Common Stock 10000 170000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of November 15, 2022. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.52 to $17.89, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.97 to $18.75, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. On May 4, 2015, the reporting person was granted an option to purchase 229,837 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter. /s/ Aby J. Mathew 2023-01-05